EP0986368A1 - Zusammensetzungen fuer die hautpflege - Google Patents

Zusammensetzungen fuer die hautpflege

Info

Publication number
EP0986368A1
EP0986368A1 EP98922411A EP98922411A EP0986368A1 EP 0986368 A1 EP0986368 A1 EP 0986368A1 EP 98922411 A EP98922411 A EP 98922411A EP 98922411 A EP98922411 A EP 98922411A EP 0986368 A1 EP0986368 A1 EP 0986368A1
Authority
EP
European Patent Office
Prior art keywords
skin
acid
esters
compositions
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98922411A
Other languages
English (en)
French (fr)
Inventor
George Endel Deckner
James Pedrosa Sanogueira, Jr.
Joseph Michael Zukowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP0986368A1 publication Critical patent/EP0986368A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • Invention relates to skin care compositions containing retinoids which generally improve the quality of the skin, particularly human facial skin. More particularly, the present invention relates to retinol containing skin care compositions with improved skin compatibility.
  • Extrinsic factors include ultraviolet radiation (e.g., from sun exposure), environmental pollution, wind, heat, low humidity, harsh surfactants, abrasives, and the like.
  • Intrinsic factors include chronological aging and other biochemical changes from within the skin. Whether extrinsic or intrinsic, these factors result in visible signs of skin aging and environmental damage, such as wrinkling and other forms of roughness (including increased pore size, flaking and skin lines), and other histological changes associated with skin aging or damage.
  • skin wrinkles are a reminder of the disappearance of youth. As a result, the elimination of wrinkles has become a booming business in youth-conscious societies. Treatments range from cosmetic creams and moisturizers to various forms of cosmetic surgery.
  • Extrinsic or intrinsic factors may result in the thinning and general degradation of the skin. For example, as the skin naturally ages, there is a reduction in the cells and blood vessels that supply the skin. There is also a flattening of the dermal-epidermal junction which results in weaker mechanical resistance of this junction. See, for example, Oikarinen, "The Aging of Skin: Chronoaging Versus Photoaging,” Photodermatol. Photoimmunol. Photomed., vol. 7, pp. 3-4, 1990, which is incorporated by reference herein in its entirety.
  • Retinoids are well recognized as anti-wrinkle actives which help to reduce the subcutaneous effects of aging as wrinkling, leatheriness, looseness, roughness, dryness, and mottling (hyper pigmentation) (see, U.S. Patents 4,603,146 and 4,877,805 to Kligman). It has been postulated that retinoids act by producing inflammation, which causes thickening of the epidermis (acanthosis), and local intercellular edema, leading to exfoliation.
  • compositions containing natural or synthetic retinoid compounds along with a preservative component comprising a formaldehyde donating preservative and a halopropynyl compound deliver the skin regulating benefits of retinoid compounds with reduced dryness and/or irritation.
  • a preservative component comprising a formaldehyde donating preservative and a halopropynyl compound
  • an object of the present invention is to provide retinoid containing skin care compositions having improved skin compatibility.
  • Another object of the present invention is to provide retinoid compositions containing preservative systems which provide preservation activity at relatively low concentrations.
  • Still another object of the present invention is to provide retinoid compositions containing preservative systems which do not substantially impact retinoid stability or bioavailability.
  • the present invention relates to skin care compositions, comprising: a.) a retinoid; and b.) a preservative component, comprising: i.) a formaldehyde donor; and ii.) a halopropynyl compound selected from the group consisting of iodopropargyl esters, ethers, acetals, carbamates and carbonates.
  • a preservative component comprising: i.) a formaldehyde donor; and ii.) a halopropynyl compound selected from the group consisting of iodopropargyl esters, ethers, acetals, carbamates and carbonates.
  • the present invention further relates to methods of regulating skin conditioning.
  • compositions of the present invention can comprise, consist essentially of, or consist of, the essential as well as optional ingredients and components described herein.
  • “consisting essentially of” means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
  • topical application means to apply or spread the compositions of the present invention onto the surface of the skin.
  • compositions or components thereof so described are suitable for use in contact with human skin without undue toxicity, incompatibility, instability, allergic response, and the like.
  • safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit, preferably a positive skin appearance or feel benefit, including independently the benefits disclosed herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan.
  • skin compatibility means the ability of skin to tolerate long term application of topical compositions with minimal adverse skin reactions such as stinging, burning, redness, itching and folliculitis.
  • compositions of the present invention are useful for topical application and for regulating skin condition, including visible and/or tactile discontinuities in skin (especially the skin surface; such discontinuities are generally undesirable). Such discontinuities may be induced or caused by internal and/or external factors, and include the signs of skin aging described herein.
  • the term "regulating skin condition” includes prophylactically regulating and/or therapeutically regulating skin condition, including visible and/or tactile discontinuities in skin.
  • prophylactically regulating skin condition includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in skin.
  • therapeutically regulating skin condition includes ameliorating, e.g., diminishing, minimizing and/or effacing, discontinuities in skin. Regulating skin condition involves improving skin appearance and/or feel.
  • compositions of the present invention are useful for regulating signs of skin aging, more especially visible and/or tactile discontinuities in skin texture associated with aging.
  • "Regulating the signs of skin aging” includes prophylactically regulating and/or therapeutically regulating one or more of such signs (similarly, regulating a given sign of skin aging, e.g., lines, wrinkles or pores, includes prophylactically regulating and/or therapeutically regulating that sign).
  • prophylactically regulating such signs includes delaying, minimizing and/or preventing signs of skin aging.
  • therapeutically regulating such signs includes ameliorating, e.g., diminishing, minimizing and/or effacing signs of skin aging.
  • “Signs of skin aging” include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging. Such signs may be induced or caused by intrinsic factors or extrinsic factors, e.g., chronological aging and/or environmental damage.
  • These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles, including both fine superficial wrinkles and coarse deep wrinkles, skin lines, crevices, bumps, large pores (e.g., associated with adnexal structures such as sweat gland ducts, sebaceous glands, or hair follicles), scaliness, flakiness and/or other forms of skin unevenness or roughness, loss of skin elasticity (loss and/or inactivation of functional skin elastin), sagging (including puffiness in the eye area and jowls), loss of skin firmness, loss of skin tightness, loss of skin recoil from deformation, discoloration (including undereye circles), blotching, sallowness, hyperpigmented skin regions such as age spots and freckles, keratoses, abnormal differentiation, hyperkeratinization, elastosis, collagen breakdown, and other histological changes in the stratum corneum, dermis, epidermis,
  • the present invention is not to be limited to regulation of the above mentioned “signs of skin aging” which arise due to mechanisms associated with skin aging, but is intended to include regulation of said signs irrespective of the mechanism of origin.
  • regulating skin condition is intended to include regulation of such signs irrespective of the mechanism of origin.
  • the present invention is especially useful for therapeutically regulating visible and/or tactile discontinuities in mammalian skin texture, including texture discontinuities associated with skin aging.
  • therapeutically regulating such discontinuities includes ameliorating, e.g., diminishing, minimizing and/or effacing visible and/or tactile discontinuities in the texture of mammalian skin, to thereby provide improved skin appearance and/or feel, e.g., a smoother, more even appearance and/or feel.
  • Such visible and/or tactile discontinuities in skin texture include crevices, bumps, pores, fine lines, wrinkles, scales, flakes and/or other forms of textural unevenness or roughness associated with skin aging. For example, the length, depth, and/or other dimension of lines and/or wrinkles are decreased, the apparent diameter of pores decreases, or the apparent height of tissue immediately proximate to pore openings approaches that of the interadnexal skin.
  • the present invention is also especially useful for prophylactically regulating visible and/or tactile discontinuities in mammalian skin texture, including texture discontinuities associated with skin aging.
  • prophylactically regulating such discontinuities includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in the texture of mammalian skin, to thereby provide improved skin appearance and/or feel, e.g., a smoother, more even appearance and/or feel.
  • retinoid includes all natural and/or synthetic analogs of Vitamin A or retinol-like compounds which possess the biological activity of Vitamin A in the skin as well as the geometric isomers and stereoisomers of these compounds.
  • the retinoid is preferably retinol, retinol esters (e.g., C2 - C22 alkyl esters of retinol, including retinyl palmitate, retinyl acetate, retinyl proprionate), retinal, and/or retinoic acid (including all-trans retinoic acid and/or 13- cis-retinoic acid), more preferably retinoids other than retinoic acid.
  • retinoids include all-trans retinoic acid and/or 13- cis-retinoic acid
  • These compounds are well known in the art and are commercially available from a number of sources, e.g., Sigma Chemical Company (St. Louis, MO), and Boerhinger Mannheim (Indianapolis, IN). Other retinoids which are useful herein are described in U.S.
  • Suitable retinoids are tocopheryl-retinoate [tocopherol ester of retinoic acid (trans- or cis-), adapalene ⁇ 6-[3-(l-adamantyl)-4- methoxyphenyl]-2-naphthoic acid ⁇ , and tazarotene (ethyl 6-[2-(4,4- dimethylthiochroman-6-yl)-ethynyl]nicotinate).
  • One or more retinoids may be used herein.
  • Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, retinyl proprionate, retinal and combinations thereof. More preferred are retinol and retinyl palmitate.
  • the retinoid may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • the retinoid is preferably substantially pure, more preferably essentially pure.
  • compositions of this invention contain a safe and effective amount of the retinoid for regulating skin condition, preferably for regulating visible and/or tactile discontinuities in skin, more preferably for regulating signs of skin aging, even more preferably for regulating visible and/or tactile discontinuities in skin texture associated with skin aging.
  • the compositions preferably contain from about 0.005% to about 2%, more preferably 0.01% to about 2%, retinoid.
  • Retinol is most preferably used in an amount of from about 0.01% to about 0.15%; retinol esters are most preferably used in an amount of from about 0.01% to about 2% (e.g., about 1%); retinoic acids are most preferably used in an amount of from about 0.01% to about 0.25%; tocopheryl-retinoate [tocopherol ester of retinoic acid (trans- or cis), adapalene ⁇ 6-[3-(l-adamantyl)-4-methoxyphenyl]-2-naphthoic acid ⁇ , and tazarotene are most preferably used in an amount of from about 0.01% to about 2%.
  • the vitamin B3 compound is preferably used in an amount of from about 0.1% to about 10%, more preferably from about 2% to about 5%.
  • a preservative component comprising a formaldehyde donor and a halopropynyl compound.
  • the preservative component of the present invention provides substantially no negative impact to the active's stability.
  • substantially no negative impact means that less than about 10% of the active is chemically degraded or otherwise altered resulting in an inactive degradation product when in the presence of the preservative component in the composition herein during a one month period at a temperature of 40°C.
  • Suitable formaldehyde donors have chemical and physical characteristics compatible with use in personal care products. Such products preferably are not odiferous or an irritant or toxic when applied to the skin.
  • suitable formaldehyde donors include dimethyloldimethylhydantoin, N,N"-methylene bis [N'-[hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]urea]; N-(hydroxymethyl)-N-(l,3- dihydroxymethyl-2,5-dioxo-4-imidazolidinyl)-N'-(hydroxymethyl) urea; the cis isomer of l-(3-chloroallyl)-3,5,7-triaza-l-azoniaadamantane chloride sodium hydroxymethylglycinate, dimethyl oxazoline 7-ethylbicycloxasolidine, 2-bromo-2- nitropropane-l,3-diol, 5-bromo-5-nitro-l,3-dioxane and mixtures thereof.
  • halopropynyl compounds include compounds derived from propargyl or iodopropargyl alcohols such as the esters, ethers, acetals, carbamates and carbonates and the iodopropargyl derivatives of pyrimidines, triazolinones, tetrazoles, triazinones, sulfamides, benzothiazoles, ammonium salts, carboxamides, hydroxamates, ureas and mixtures thereof.
  • Preferred among these compounds is 3-iodo-2-propynylbutyl carbamate (IPBC). This compound is included within the broadly useful class of compounds having the generic formula:
  • R is selected from the group consisting of substituted and unsubstituted alkyl, aryl and alkylaryl groups having from 1 to 20 carbon atoms, and m and n are independent integers from 1 to 3.
  • the weight ratio of the two components varies depending on the application and the particular component selected. Broadly speaking, the weight ratio varies from about 2000:1 to about 1 :1 parts of the first to the second component may be used, preferably from about 500:1 to about 1 :1, most preferably from about 200:1 to about 1 :1, the parts being by weight.
  • the preservative component of the present invention is present at a concentration of from about 0.001% to about 5%, preferably from about 0.01% to about 3%, more preferably from about 0.01% to about 2%, more preferably from about 0.05% to about 1% and most preferably from about 0.05% to about 0.2%.
  • compositions of the present invention comprise from about 1% to about 99.5% of a dermatologically acceptable carrier within which the essential retinoid and preservative component and optional other materials are incorporated to enable these components to be delivered to the skin at an appropriate concentration.
  • the carrier can thus act as a diluent, dispersant, solvent, or the like for the particulate material which ensures that it can be applied to and distributed evenly over the selected target at an appropriate concentration.
  • the carrier may contain one or more dermatologically acceptable solid, semi- solid or liquid fillers, diluents, solvents, extenders and the like.
  • the carrier may be solid, semi-solid or liquid. Preferred carriers are substantially liquid.
  • the carrier can itself be inert or it can possess dermatological benefits of its own. Concentrations of the carrier can vary with the carrier selected and the intended concentrations of the essential and optional components.
  • Suitable carriers include conventional or otherwise known carriers that are dermatologically acceptable.
  • the carrier should also be physically and chemically compatible with the essential components described herein, and should not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention.
  • Preferred components of the compositions of this invention should be capable of being comingled in a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations.
  • the type of carrier utilized in the present invention depends on the type of product form desired for the composition.
  • the topical compositions useful in the subject invention may be made into a wide variety of product forms such as are known in the art. These include, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, pastes, mousses and cosmetics (e.g., solid, semi-solid, or liquid make-up, including foundations, eye-makeup, pigmented or non-pigmented lip treatments, e.g., lipsticks, and the like).
  • These product forms may comprise several types of carriers including, but not limited to, solutions, aerosols, emulsions, gels, solids, and liposomes.
  • Preferred carriers contain a dermatologically acceptable, hydrophilic diluent.
  • hydrophilic diluent includes materials in which the particulate material can be dispersed, dissolved, or otherwise inco ⁇ orated.
  • hydrophilic diluents are water, organic hydrophilic diluents such as lower monovalent alcohols (e.g., C ⁇ - C4) and low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g., Molecular Weight 200-600 g/mole), polypropylene glycol (e.g., Molecular Weight 425-2025 g/mole), glycerol, butylene glycol, 1 ,2,4-butanetriol, sorbitol esters, 1 ,2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, ether propanol, ethoxylated ethers
  • Solutions according to the subject invention typically include a dermatologically acceptable hydrophilic diluent. Solutions useful in the subject invention preferably contain from about 60% to about 99.99% of the hydrophilic diluent.
  • Aerosols according to the subject invention can be formed by adding a propellant to a solution such as described above.
  • propellants include chloro-fluorinated lower molecular weight hydrocarbons. Additional propellants that are useful herein are described in Sagarin, Cosmetics Science and Technology. 2nd Edition, Vol. 2, pp. 443-465 (1972), incorporated herein by reference. Aerosols are typically applied to the skin as a spray-on product.
  • Preferred carriers comprise an emulsion comprising a hydrophilic phase comprising a hydrophilic component, e.g., water or other hydrophilic diluent, and a hydrophobic phase comprising a hydrophobic component, e.g., a lipid, oil or oily material.
  • a hydrophilic phase will be dispersed in the hydrophobic phase, or vice versa, to form respectively hydrophilic or hydrophobic dispersed and continuous phases, depending on the composition ingredients.
  • the term "dispersed phase” is a term well- known to one skilled in the art which means that the phase exists as small particles or droplets that are suspended in and surrounded by a continuous phase.
  • the dispersed phase is also known as the internal or discontinuous phase.
  • the emulsion may be or comprise (e.g., in a triple or other multi-phase emulsion) an oil-in-water emulsion or a water-in-oil emulsion such as a water-in-silicone emulsion.
  • Oil-in- water emulsions typically comprise from about 1% to about 50% of the dispersed hydrophobic phase and from about 1% to about 98% of the continuous hydrophilic phase; water-in-oil emulsions typically comprise from about 1% to about 98% of the dispersed hydrophilic phase and from about 1% to about 50% of the continuous hydrophobic phase.
  • the emulsion may also comprise a gel network, such as described in "Application of Emulsion Stability Grafs to Mobile and Semisolid Oil-in-Water Emulsions", Cosmetics and Toiletries, vol. 101, November 1986, pp. 73-92, which is incorporated by reference herein. Preferred emulsions are further described below.
  • compositions of the subject invention may comprise a dermatologically acceptable emollient.
  • emollients may contain from about 2% to about 50% of the emollient.
  • Emollients tend to lubricate the skin, increase the smoothness and suppleness of the skin, prevent or relieve dryness of the skin, and/or protect the skin.
  • Emollients are typically water-immiscible, oily or waxy materials.
  • suitable emollients are known and may be used herein. Sagarin, Cosmetics. Science and Technology. 2nd Edition, Vol. 1, pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of materials suitable as an emollient.
  • Lotions and creams according to the present invention generally comprise a solution carrier system and one or more emollients.
  • Lotions typically comprise from about 1% to about 20%, preferably from about 5% to about 10%, of emollient; from about 50% to about 90%, preferably from about 60% to about 80%, water.
  • a cream typically comprises from about 5% to about 50%, preferably from about 10% to about 20%, of emollient; and from about 45% to about 85%, preferably from about 50% to about 75%, water.
  • Ointments of the present invention may comprise a simple carrier base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous); absorption ointment bases which absorb water to form emulsions; or water soluble carriers, e.g., a water soluble solution carrier.
  • Ointments may further comprise a thickening agent, such as described in Sagarin, Cosmetics. Science and Technology. 2nd Edition, Vol. 1, pp. 72-73 (1972), incorporated herein by reference, and/or an emollient.
  • an ointment may comprise from about 2% to about 10% of an emollient; and from about 0.1% to about 2% of a thickening agent.
  • compositions of this invention useful for cleansing are formulated with a suitable carrier, e.g., as described above, and preferably contain one or more dermatologically acceptable surfactants in an amount which is safe and effective for cleansing.
  • a suitable carrier e.g., as described above
  • Preferred compositions contain from about 1% to about 90%, more preferably from about 5% to about 10%, of a dermatologically acceptable surfactant.
  • the surfactant is suitably selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants.
  • Such surfactants are well known to those skilled in the detergency art.
  • Nonlimiting examples of possible surfactants include isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, and betaines such as described herein. See U.S. Patent No. 4,800,197, to Kowcz et al., issued January 24, 1989, which is incorporated herein by reference in its entirety, for exemplary surfactants useful herein. Examples of a broad variety of additional surfactants useful herein are described in McCutcheon's Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Corporation, which is incorporated herein by reference in its entirety.
  • the cleansing compositions can optionally contain, at their art-established levels, other materials which are conventionally used in cleansing compositions.
  • the physical form of the cleansing compositions is not critical.
  • the compositions can be, for example, formulated as toilet bars, liquids, shampoos, bath gels, hair conditioners, hair tonics, pastes, or mousses. Toilet bars are most preferred since this is the form of cleansing agent most commonly used to wash the skin.
  • Preferred rinse-off cleansing compositions, such as shampoos include a delivery system adequate to deposit sufficient levels of actives on the skin and scalp.
  • a preferred delivery system involves the use of insoluble complexes. For a more complete disclosure of such delivery systems, see U.S. Patent 4,835,148, Barford et al., issued May 30, 1989, incorporated herein by reference in its entirety.
  • the term "foundation” refers to a liquid, semi-liquid, semisolid, or solid skin cosmetic which includes, but is not limited to lotions, creams, gels, pastes, cakes, and the like. Typically the foundation is used over a large area of the skin, such as over the face, to provide a particular look. Foundations are typically used to provide an adherent base for color cosmetics such as rouge, blusher, powder and the like, and tend to hide skin imperfections and impart a smooth, even appearance to the skin. Foundations of the present invention include a dermatologically acceptable carrier for the essential particulate material and may include conventional ingredients such as oils, colorants, pigments, emollients, fragrances, waxes, stabilizers, and the like.
  • compositions of the present invention are preferably formulated to have a pH of 10.5 or below.
  • the pH values of these compositions preferably range from about 2 to about 10.5, more preferably from about 3 to about 8, even more preferably from about 5 to about 8.
  • compositions of the present invention comprise an emulsion.
  • Emulsions of the present invention may contain one or more of the following:
  • Emulsions according to the present invention contain a hydrophobic phase comprising a lipid, oil, oily or other hydrophobic component.
  • the compositions of the present invention preferably comprise from about 1% to about 50%, preferably from about 1% to about 30%, and more preferably from about 1% to about 10% by weight of the composition of a hydrophobic component.
  • the hydrophobic component may be derived from animals, plants, or petroleum and may be natural or synthetic (i.e., man-made).
  • Preferred hydrophobic components are substantially water-insoluble, more preferably essentially water-insoluble.
  • Preferred hydrophobic components are those having a melting point of about 25°C or less under about one atmosphere of pressure, and are suitable for conditioning the skin or hair.
  • suitable hydrophobic components include those selected from the group consisting of:
  • Mineral oil which is also known as petrolatum liquid, is a mixture of liquid hydrocarbons obtained from petroleum. See The Merck Index, Tenth Edition, Entry 7048, p. 1033 (1983) and International Cosmetic Ingredient Dictionary, Fifth Edition, vol. 1, p.415-417 (1993), which are inco ⁇ orated by reference herein in their entirety.
  • Petrolatum which is also known as petroleum jelly, is a colloidal system of nonstraight-chain solid hydrocarbons and high-boiling liquid hydrocarbons, in which most of the liquid hydrocarbons are held inside the micelles. See The Merck Index, Tenth Edition, Entry 7047, p. 1033 (1983); Schindler, Drug. Cosmet. Ind.. 89, 36- 37, 76, 78-80, 82 (1961); and International Cosmetic Ingredient Dictionary, Fifth Edition, vol. 1, p. 537 (1993), which are inco ⁇ orated by reference herein in their entirety.
  • Straight and branched chain hydrocarbons having from about 7 to about 40 carbon atoms.
  • these hydrocarbon materials include dodecane, isododecane, squalane, cholesterol, hydrogenated polyisobutylene, docosane (i.e. a C22 hydrocarbon), hexadecane, isohexadecane (a commercially available hydrocarbon sold as Permethyl® 101 A by Presperse, South Plainfield, NJ).
  • docosane i.e. a C22 hydrocarbon
  • hexadecane isohexadecane
  • C7-C40 isoparaffins which are C7-C40 branched hydrocarbons.
  • C1-C30 alcohol esters of C1-C30 carboxylic acids and of C2-C30 dicarboxylic acids including straight and branched chain materials as well as aromatic derivatives (as used herein in reference to the hydrophobic component, mono- and poly- carboxylic acids include straight chain, branched chain and aryl carboxylic acids).
  • Nonlimiting examples include diisopropyl sebacate, diisopropyl adipate, isopropyl myristate, isopropyl palmitate, methyl palmitate, myristyl propionate, 2-ethylhexyl palmitate, isodecyl neopentanoate, di-2-ethylhexyl maleate, cetyl palmitate, myristyl myristate, stearyl stearate, isopropyl stearate, methyl stearate, cetyl stearate, behenyl behenrate, dioctyl maleate, dioctyl sebacate, diisopropyl adipate, cetyl octanoate, diisopropyl dilinoleate.
  • mono-, di- and tri- glycerides of C1-C30 carboxylic acids e.g., caprilic/capric triglyceride, PEG-6 caprylic/capric triglyceride, PEG-8 caprylic/capric triglyceride.
  • alkylene glycol esters of C1-C30 carboxylic acids e.g., ethylene glycol mono- and di- esters, and propylene glycol mono- and di- esters of C1-C30 carboxylic acids e.g., ethylene glycol distearate.
  • esters of sugars and related materials. These esters are derived from a sugar or polyol moiety and one or more carboxylic acid moieties. Depending on the constituent acid and sugar, these esters can be in either liquid or solid form at room temperature.
  • liquid esters include: glucose tetraoleate, the glucose tetraesters of soybean oil fatty acids (unsaturated), the mannose tetraesters of mixed soybean oil fatty acids, the galactose tetraesters of oleic acid, the arabinose tetraesters of linoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, the sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate, sucrose pentaoletate, sucrose hexaoleate, sucrose hepatoleate, sucrose octaoleate, and mixtures thereof.
  • solid esters include: sorbitol hexaester in which the carboxylic acid ester moieties are palmitoleate and arachidate in a 1 :2 molar ratio; the octaester of raffinose in which the carboxylic acid ester moieties are linoleate and behenate in a 1 :3 molar ratio; the heptaester of maltose wherein the esterifying carboxylic acid moieties are sunflower seed oil fatty acids and lignocerate in a 3:4 molar ratio; the octaester of sucrose wherein the esterifying carboxylic acid moieties are oleate and behenate in a 2:6 molar ratio; and the octaester of sucrose wherein the esterifying carboxylic acid moieties are laurate, linoleate and behenate in a 1 :3:4 molar ratio.
  • a preferred solid material is sucrose polyester in which the degree of esterification is 7-8, and in which the fatty acid moieties are C18 mono- and/or di -unsaturated and behenic, in a molar ratio of unsaturates:behenic of 1:7 to 3:5.
  • a particularly preferred solid sugar polyester is the octaester of sucrose in which there are about 7 behenic fatty acid moieties and about 1 oleic acid moiety in the molecule.
  • Other materials include cottonseed oil or soybean oil fatty acid esters of sucrose.
  • the ester materials are further described in, U.S. Patent No. 2,831,854, U.S. Patent No. 4,005,196, to Jandacek, issued January 25, 1977; U.S. Patent No.
  • Organopolysiloxane oils may be volatile, nonvolatile, or a mixture of volatile and non-volatile silicones.
  • the term "nonvolatile” as used in this context refers to those silicones that are liquid under ambient conditions and have a flash point (under one atmospheric of pressure) of or greater than about 100°C.
  • the term "volatile” as used in this context refers to all other silicone oils.
  • Suitable organopolysiloxanes can be selected from a wide variety of silicones spanning a broad range of volatilities and viscosities. Nonvolatile polysiloxanes are preferred. Nonlimiting examples of suitable silicones are disclosed in U.S. Patent No.
  • organopolysiloxane oils include polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes.
  • Polyalkylsiloxanes useful in the composition herein include polyalkylsiloxanes with viscosities of from about 0.5 to about 1,000,000 centistokes at 25 °C.
  • Such polyalkylsiloxanes can be represented by the general chemical formula R3SiO[R2SiO] x SiR3 wherein R is an alkyl group having from one to about 30 carbon atoms (preferably R is methyl or ethyl, more preferably methyl; also mixed alkyl groups can be used in the same molecule), and x is an integer from 0 to about 10,000, chosen to achieve the desired molecular weight which can range to over about 10,000,000.
  • polyalkylsiloxanes include the polydimethylsiloxanes, which are also known as dimethicones, examples of which include the Vicasil® series sold by General Electric Company and the Dow Corning ® 200 series sold by Dow Corning Co ⁇ oration.
  • suitable polydimethylsiloxanes include Dow Corning® 200 fluid having a viscosity of 0.65 centistokes and a boiling point of 100°C, Dow Corning® 225 fluid having a viscosity of 10 centistokes and a boiling point greater than 200°C, and Dow Corning ® 200 fluids having viscosities of 50, 350, and 12,500 centistokes, respectively, and boiling points greater than 200°C.
  • Suitable dimethicones include those represented by the chemical formula (CH3)3SiO[(CH3)2SiO] x [CH3RSiO] y Si(CH3)3 wherein R is straight or branched chain alkyl having from two to about 30 carbon atoms and x and y are each integers of 1 or greater selected to achieve the desired molecular weight which can range to over about 10,000,000.
  • alkyl- substituted dimethicones include cetyl dimethicone and lauryl dimethicone.
  • Cyclic polyalkylsiloxanes suitable for use in the composition include those represented by the chemical formula [SiR2-O] n wherein R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and n is an integer from about 3 to about 8, more preferably n is an integer from about 3 to about 7, and most preferably n is an integer from about 4 to about 6.
  • R is an alkyl group
  • n is an integer from about 3 to about 8
  • preferably n is an integer from about 3 to about 7
  • most preferably n is an integer from about 4 to about 6.
  • R is methyl
  • these materials are typically referred to as cyclomethicones.
  • Commercially available cyclomethicones include Dow Corning® 244 fluid having a viscosity of 2.5 centistokes, and a boiling point of 172°C, which primarily contains the cyclomethicone tetramer (i.e.
  • Dow Corning® 245 fluid having a viscosity of 4.2 centistokes and a boiling point of 205°C, which primarily contains a mixture of the cyclomethicone tetramer and pentamer (i.e.
  • n 4 and 5
  • Dow Corning® 345 fluid having a viscosity of 4.5 centistokes and a boiling point of 217°, which primarily contains a mixture of the cyclomethicone tetramer, pentamer, and hexamer (i.e. n-4, 5, and 6).
  • trimethylsiloxysilicate which is a polymeric material corresponding to the general chemical formula [(CH2)3SiO ⁇ /2] x [Si ⁇ 2]y, wherein x is an integer from about 1 to about 500 and y is an integer from about 1 to about 500.
  • a commercially available trimethylsiloxysilicate is sold as a mixture with dimethicone as Dow Corning® 593 fluid.
  • Dimethiconols are also suitable for use in the composition. These compounds can be represented by the chemical formulas R3SiO[R2SiO] x SiR2OH and HOR2SiO[R2SiO] x SiR2OH wherein R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and x is an integer from 0 to about 500, chosen to achieve the desired molecular weight.
  • R is an alkyl group (preferably R is methyl or ethyl, more preferably methyl) and x is an integer from 0 to about 500, chosen to achieve the desired molecular weight.
  • Commercially available dimethiconols are typically sold as mixtures with dimethicone or cyclomethicone (e.g. Dow Corning® 1401, 1402, and 1403 fluids).
  • Polyalkylaryl siloxanes are also suitable for use in the composition.
  • Polymethylphenyl siloxanes having viscosities from about 15 to about 65 centistokes at 25°C are especially useful.
  • organopolysiloxanes selected from the group consisting of polyalkylsiloxanes, alkyl substituted dimethicones, cyclomethicones, trimethylsiloxysilicates, dimethiconols, polyalkylaryl siloxanes, and mixtures thereof. More preferred for use herein are polyalkylsiloxanes and cyclomethicones. Preferred among the polyalkylsiloxanes are dimethicones.
  • Vegetable oils and hydrogenated vegetable oils examples include safflower oil, castor oil, coconut oil, cottonseed oil, menhaden oil, palm kernel oil, palm oil, peanut oil, soybean oil, rapeseed oil, linseed oil, rice bran oil, pine oil, sesame oil, sunflower seed oil, hydrogenated safflower oil, hydrogenated castor oil, hydrogenated coconut oil, hydrogenated cottonseed oil, hydrogenated menhaden oil, hydrogenated palm kernel oil, hydrogenated palm oil, hydrogenated peanut oil, hydrogenated soybean oil, hydrogenated rapeseed oil, hydrogenated linseed oil, hydrogenated rice bran oil, hydrogenated sesame oil, hydrogenated sunflower seed oil, and mixtures thereof.
  • animal fats and oils e.g., lanolin and derivatives thereof, cod liver oil.
  • C4-C20 alkyl ethers of polypropylene glycols are also useful.
  • C1-C20 carboxylic acid esters of polypropylene glycols include di-C8-C30 alkyl ethers.
  • Nonlimiting examples of these materials include PPG- 14 butyl ether, PPG- 15 stearyl ether, dioctyl ether, dodecyl octyl ether, and mixtures thereof.
  • Emulsions of the present invention also comprise a hydrophilic component, e.g., water or other hydrophilic diluent.
  • the hydrophilic phase can thus comprise water, or a combination of water and one or more water soluble or dispersible ingredients. Hydrophilic components comprising water are preferred.
  • Emulsions and other topical compositions of the present invention may comprise a variety of other ingredients such as disclosed herein. As will be understood by the skilled artisan, a given component will distribute primarily into either a hydrophilic phase or hydrophobic phase, depending on the hydrophilicity of the component in the composition.
  • Emulsions of the present invention preferably include one or more compounds selected from emulsifiers, surfactants, structuring agents, and thickeners.
  • Emulsifiers/Surfactants preferably include one or more compounds selected from emulsifiers, surfactants, structuring agents, and thickeners.
  • the emulsion may contain an emulsifier and/or surfactant, generally to help disperse and suspend the discontinuous phase within the continuous phase.
  • an emulsifier and/or surfactant generally to help disperse and suspend the discontinuous phase within the continuous phase.
  • emulsifiers/surfactants can be employed.
  • Known or conventional emulsifiers/surfactants can be used in the composition, provided that the selected agent is chemically and physically compatible with essential components of the composition, and provides the desired dispersion characteristics.
  • Suitable agents include non-silicone-containing emulsifiers/surfactants, silicone emulsifiers/surfactants, and mixtures thereof.
  • the composition comprises a hydrophilic emulsifier or surfactant.
  • the compositions of the present invention preferably comprise from about 0.05% to about 5%, more preferably from about 0.05% to about 1% of at least one hydrophilic surfactant.
  • the hydrophilic surfactant assists in dispersing hydrophobic materials, e.g., hydrophobic structuring agents, in the hydrophilic phase.
  • the surfactant at a minimum, must be hydrophilic enough to disperse in the hydrophilic phase.
  • Preferred surfactants are those having an HLB of at least about 8. The exact surfactant chosen will depend upon the pH of the composition and the other components present.
  • Preferred hydrophilic surfactants are selected from nonionic surfactants.
  • nonionic surfactants that are useful herein are those that can be broadly defined as condensation products of long chain alcohols, e.g. C8-30 alcohols, with sugar or starch polymers, i.e., glycosides. These compounds can be represented by the formula (S) n -O-R wherein S is a sugar moiety such as glucose, fructose, mannose, and galactose; n is an integer of from about 1 to about 1000, and R is a C8-30 alkyl group.
  • long chain alcohols from which the alkyl group can be derived include decyl alcohol, cetyl alcohol, stearyl alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol, and the like.
  • Preferred examples of these surfactants include those wherein S is a glucose moiety, R is a C8-20 alkyl group, and n is an integer of from about 1 to about 9.
  • Commercially available examples of these surfactants include decyl polyglucoside (available as APG 325 CS from Henkel) and lauryl polyglucoside (available as APG 600 CS and 625 CS from Henkel).
  • Nonionic surfactants include the condensation products of alkylene oxides with fatty acids (i.e. alkylene oxide esters of fatty acids). These materials have the general formula RCO(X) n OH wherein R is a C 10-30 alkyl group, X is -OCH 2 CH - (i.e. derived from ethylene glycol or oxide) or -OCH 2 CHCH 3 - (i.e. derived from propylene glycol or oxide), and n is an integer from about 6 to about 200.
  • Other nonionic surfactants are the condensation products of alkylene oxides with 2 moles of fatty acids (i.e. alkylene oxide diesters of fatty acids).
  • RCO(X) n OOCR wherein R is a C 10-30 alkyl group, X is -OCH2CH2-(i.e. derived from ethylene glycol or oxide) or - OCH2CHCH3-(i.e. derived from propylene glycol or oxide), and n is an integer from about 6 to about 100.
  • Other nonionic surfactants are the condensation products of alkylene oxides with fatty alcohols (i.e. alkylene oxide ethers of fatty alcohols).
  • R(X) n OR' wherein R is a C 10-30 alkyl group, X is -OCH2CH2-(i.e.
  • nonionic surfactants are the condensation products of alkylene oxides with both fatty acids and fatty alcohols [i.e. wherein the polyalkylene oxide portion is esterified on one end with a fatty acid and etherified (i.e. connected via an ether linkage) on the other end with a fatty alcohol].
  • RCO(X) n OR' wherein R and R' are C 10-30 alkyl groups, X is -OCH2CH2 (i.e.
  • Nonlimiting examples of these alkylene oxide derived nonionic surfactants include ceteth-6, ceteth-10, ceteth-12, ceteareth-6, ceteareth-10, ceteareth-12, steareth-6, steareth-10, steareth-12, PEG-6 stearate, PEG- 10 stearate, PEG- 100 stearate, PEG- 12 stearate, PEG-20 glyceryl stearate, PEG-80 glyceryl tallowate, PEG- 10 glyceryl stearate, PEG-30 glyceryl cocoate, PEG-80 glyceryl cocoate, PEG-200 glyceryl tallowate, PEG-8 dilaurate, PEG- 10 distearate, and mixtures thereof.
  • Still other useful nonionic surfactants include polyhydroxy fatty acid amide surfactants corresponding to the structural formula:
  • R is H, C. -C . alkyl, 2-hydroxy ethyl, 2-hydroxy- propyl, preferably
  • R is
  • alkyl or alkenyl preferably C 7 -C .
  • Q alkyl or alkenyl more preferably
  • Z preferably is a sugar moiety selected from the group consisting of glucose, fructose, maltose, lactose, galactose, mannose, xylose, and mixtures thereof.
  • An especially preferred surfactant corresponding to the above structure is coconut alkyl N-methyl glucoside amide (i.e., wherein the
  • compositions containing polyhydroxy fatty acid amides are disclosed, for example, in G.B. Patent Specification 809,060, published February 18, 1959, by Thomas Hedley & Co., Ltd.; U.S. Patent No. 2,965,576, to E. R. Wilson, issued December 20, 1960; U.S. Patent No. 2,703,798, to A. M. Schwartz, issued March 8, 1955; and U.S. Patent No. 1,985,424, to Piggott, issued December 25, 1934; which are inco ⁇ orated herein by reference in their entirety.
  • nonionic surfactants are those selected from the group consisting of steareth-21, ceteareth-20, ceteareth-12, sucrose cocoate, steareth-100, PEG- 100 stearate, and mixtures thereof.
  • nonionic surfactants suitable for use herein include sugar esters and polyesters, alkoxylated sugar esters and polyesters, C1-C30 fatty acid esters of Cl- C30 fatty alcohols, alkoxylated derivatives of C1-C30 fatty acid esters of C1-C30 fatty alcohols, alkoxylated ethers of C1-C30 fatty alcohols, polyglyceryl esters of C1-C30 fatty acids, C1-C30 esters of polyols, C1-C30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, and mixtures thereof.
  • Nonlimiting examples of these non-silicon- containing emulsifiers include: polyethylene glycol 20 sorbitan monolaurate (Polysorbate 20), polyethylene glycol 5 soya sterol, Steareth-20, Ceteareth-20, PPG- 2 methyl glucose ether distearate, Ceteth-10, Polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, Polysorbate 60, glyceryl stearate, polyoxyethylene 20 sorbitan trioleate (Polysorbate 85), sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, PPG-2 methyl glucose ether distearate, PEG- 100 stearate, and mixtures thereof.
  • Polysorbate 20 polyethylene glycol 5 soya sterol
  • Steareth-20 Ceteareth-20
  • emulsifier useful herein are fatty acid ester blends based on a mixture of sorbitan or sorbitol fatty acid ester and sucrose fatty acid ester, the fatty acid in each instance being preferably Cg-C24, more preferably Ci Q-C20-
  • the preferred fatty acid ester emulsifier is a blend of sorbitan or sorbitol C16-C20 fatty acid ester with sucrose C10-C16 fatty acid ester, especially sorbitan stearate and sucrose cocoate. This is commercially available from ICI under the trade name Arlatone 2121.
  • hydrophilic surfactants useful herein can alternatively or additionally include any of a wide variety of cationic, anionic, zwitterionic, and amphoteric surfactants such as are known in the art. See, e.g., McCutcheon's, Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Co ⁇ oration; U.S. Patent No. 5,011,681 to Ciotti et al., issued April 30, 1991; U.S. Patent No. 4,421,769 to Dixon et al., issued December 20, 1983; and U.S. Patent No. 3,755,560 to Dickert et al., issued August 28, 1973; these four references are inco ⁇ orated herein by reference in their entirety.
  • Exemplary cationic surfactants useful herein include those disclosed in U.S. Patent No. 5,151,209, to McCall et al., issued September 29, 1992; U.S. Patent No. 5,151,210, to Steuri et al., issued September 29, 1992; U.S. Patent No. 5,120,532, to Wells et al., issued June 9, 1992; U.S. Patent No. 4,387,090, to Bolich, issued June 7, 1983;; U.S. Patent 3,155,591, Spotifyr, issued November 3, 1964; U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975; U.S. Patent No.
  • cationic surfactants useful herein include cationic ammonium salts such as quaternary ammonium salts, and amino-amides.
  • anionic surfactants are also useful herein. See, e.g., U.S. Patent No. 3,929,678, to Laughlin et al., issued December 30, 1975, which is inco ⁇ orated herein by reference in its entirety.
  • anionic surfactants include the alkoyl isethionates (e.g., Cj2 - C30), alkyl and alkyl ether sulfates and salts thereof, alkyl and alkyl ether phosphates and salts thereof, alkyl methyl taurates (e.g., Cj2 ⁇ C30 and soaps (e.g., alkali metal salts, e.g., sodium or potassium salts) of fatty acids.
  • alkoyl isethionates e.g., Cj2 - C30
  • alkyl and alkyl ether sulfates and salts thereof alkyl and alkyl ether phosphates and salts thereof
  • alkyl methyl taurates e.g., Cj2 ⁇ C30
  • soaps e.g., alkali metal salts, e.g., sodium or potassium salts
  • amphoteric and zwitterionic surfactants are also useful herein.
  • amphoteric and zwitterionic surfactants which can be used in the compositions of the present invention are those which are broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 22 carbon atoms (preferably Cg - Ci g) and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • alkyl imino acetates examples are alkyl imino acetates, and iminodialkanoates and aminoalkanoates, imidazolinium and ammonium derivatives.
  • Other suitable amphoteric and zwitterionic surfactants are those selected from the group consisting of betaines, sultaines, hydroxysultaines, alkyl sarcosinates (e.g., C12 - C30), and alkanoyl sarcosinates.
  • Preferred emulsions of the present invention include a silicone containing emulsifier or surfactant.
  • silicone emulsifiers are useful herein. These silicone emulsifiers are typically organically modified organopolysiloxanes, also known to those skilled in the art as silicone surfactants.
  • Useful silicone emulsifiers include dimethicone copolyols. These materials are polydimethyl siloxanes which have been modified to include polyether side chains such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains, and polyether chains containing moieties derived from both ethylene oxide and propylene oxide.
  • dimethicone copolyols examples include alkyl-modified dimethicone copolyols, i.e., compounds which contain C2-C30 pendant side chains.
  • Still other useful dimethicone copolyols include materials having various cationic, anionic, amphoteric, and zwitterionic pendant moieties.
  • dimethicone copolyol emulsifiers useful herein can be described by the following general structure: CH 3 CH 3 CH 3 CH 3 CH 3
  • R is C1-C30 straight, branched, or cyclic alkyl and R ⁇ is selected from the group consisting of
  • R ⁇ and R ⁇ are selected from the group consisting of H and C1-C6 straight or branched chain alkyl such that R- ⁇ and R ⁇ are not simultaneously the same; and m, o, x, and y are selected such that the molecule has an overall molecular weight from about 200 to about 10,000,000, with m, o, x, and y being independently selected from integers of zero or greater such that m and o are not both simultaneously zero, and z being independently selected from integers of 1 or greater. It is recognized that positional isomers of these copolyols can be achieved.
  • the chemical representations depicted above for the R ⁇ moieties containing the R ⁇ and R ⁇ groups are not meant to be limiting but are shown as such for convenience.
  • silicone surfactants as depicted in the structures in the previous paragraph wherein R ⁇ is: wherein R ⁇ is a cationic, anionic, amphoteric, or zwitterionic moiety.
  • Nonlimiting examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers herein include polydimethylsiloxane polyether copolymers with pendant polyethylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed polyethylene oxide and polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed poly(ethylene)(propylene)oxide sidechains, polydimethylsiloxane polyether copolymers with pendant organobetaine sidechains, polydimethylsiloxane polyether copolymers with pendant carboxylate sidechains, polydimethylsiloxane polyether copolymers with pendant quaternary ammonium sidechains; and also further modifications of the preceding copolymers containing pendant C2-C30 straight, branched, or cyclic alky
  • dimethicone copolyols useful herein sold by Dow Corning Co ⁇ oration are Dow Corning® 190, 193, Q2-5220, 2501 Wax, 2-5324 fluid, and 3225C (this later material being sold as a mixture with cyclomethicone). Cetyl dimethicone copolyol is commercially available as a mixture with polyglyceryl-4 isostearate (and) hexyl laurate and is sold under the tradename ABIL® WE-09 (available from Goldschmidt).
  • Cetyl dimethicone copolyol is also commercially available as a mixture with hexyl laurate (and) polyglyceryl-3 oleate (and) cetyl dimethicone and is sold under the tradename ABIL® WS-08 (also available from Goldschmidt).
  • dimethicone copolyols also include lauryl dimethicone copolyol, dimethicone copolyol acetate, dimethicone copolyol adipate, dimethicone copolyolamine, dimethicone copolyol behenate, dimethicone copolyol butyl ether, dimethicone copolyol hydroxy stearate, dimethicone copolyol isostearate, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyol phosphate, and dimethicone copolyol stearate. See International Cosmetic Ingredient Dictionary. Fifth Edition, 1993, which is inco ⁇ orated by reference herein in its entirety.
  • Dimethicone copolyol emulsifiers useful herein are described, for example, in U.S. Patent No. 4,960,764, to Figueroa, Jr. et al., issued October 2, 1990; European Patent No. EP 330,369, to SaNogueira, published August 30, 1989; G. H. Dahms, et al., "New Formulation Possibilities Offered by Silicone Copolyols," Cosmetics & Toiletries, vol. 110, pp. 91-100, March 1995; M. E. Carlotti et al., "Optimization of W/O-S Emulsions And Study Of The Quantitative Relationships Between Ester Structure And Emulsion Properties," J. Dispersion Science And Technology.
  • compositions hereof, and especially the emulsions hereof may contain a structuring agent.
  • Structuring agents are particularly preferred in the oil-in-water emulsions of the present invention.
  • the structuring agent assists in providing rheological characteristics to the composition which contribute to the stability of the composition.
  • the structuring agent tends to assist in the formation of the liquid crystalline gel network structures.
  • the structuring agent may also function as an emulsifier or surfactant.
  • Preferred compositions of this invention comprise from about 1% to about 20%, more preferably from about 1% to about 10%, most preferably from about 2% to about 9%, of one or more structuring agents.
  • Preferred structuring agents are those having an HLB of from about 1 to about 8 and having a melting point of at least about 45°C.
  • Suitable structuring agents are those selected from the group consisting of saturated C ⁇ A to C30 fatty alcohols, saturated Ci g to C30 fatty alcohols containing from about 1 to about 5 moles of ethylene oxide, saturated C ⁇ to C30 diols, saturated Ci g to C30 monoglycerol ethers, saturated C ⁇ to C30 hydroxy fatty acids, C14 to C30 hydroxylated and nonhydroxylated saturated fatty acids, C14 to C30 saturated ethoxylated fatty acids, amines and alcohols containing from about 1 to about 5 moles of ethylene oxide diols, C14 to C30 saturated glyceryl mono esters with a monoglyceride content of at least 40%, C14 to C30 saturated polyglycerol esters having from about 1 to about 3 alkyl group and from about 2 to about 3 saturated glycerol units, C14
  • the preferred structuring agents of the present invention are selected from the group consisting of stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 5 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.
  • More preferred structuring agents of the present invention are selected from the group consisting of stearyl alcohol, cetyl alcohol, behenyl alcohol, the polyethylene glycol ether of stearyl alcohol having an average of about 2 ethylene oxide units (steareth-2), the polyethylene glycol ether of cetyl alcohol having an average of about 2 ethylene oxide units, and mixtures thereof. Even more preferred structuring agents are selected from the group consisting of stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steareth-2, and mixtures thereof.
  • Thickening Agent including thickeners and gelling agents
  • compositions of the present invention can also comprise a thickening agent, preferably from about 0.1% to about 5%, more preferably from about 0.1% to about 3%, and most preferably from about 0.25% to about 2%, of a thickening agent.
  • Nonlimiting classes of thickening agents include those selected from the group consisting of:
  • Carboxylic Acid Polymers These polymers are crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol.
  • the preferred carboxylic acid polymers are of two general types.
  • the first type of polymer is a crosslinked homopolymer of an acrylic acid monomer or derivative thereof (e.g., wherein the acrylic acid has substituents on the two and three carbon positions independently selected from the group consisting of C ⁇ .A alkyl, -CN, -COOH, and mixtures thereof).
  • the second type of polymer is a crosslinked copolymer having a first monomer selected from the group consisting of an acrylic acid monomer or derivative thereof (as just described in the previous sentence), a short chain alcohol (i.e., a C1.4) acrylate ester monomer or derivative thereof (e.g., wherein the acrylic acid portion of the ester has substituents on the two and three carbon positions independently selected from the group consisting of C alkyl, -CN, -COOH, and mixtures thereof), and mixtures thereof; and a second monomer which is a long chain alcohol (i.e. Cg.
  • acrylate ester monomer or derivative thereof e.g., wherein the acrylic acid portion of the ester has substituents on the two and three carbon positions independently selected from the group consisting of Cj_4 alkyl, -CN, -COOH, and mixtures thereof. Combinations of these two types of polymers are also useful herein.
  • the monomers are preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid, and mixtures thereof, with acrylic acid being most preferred.
  • the acrylic acid monomer or derivative thereof is preferably selected from the group consisting of acrylic acid, methacrylic acid, ethacrylic acid, and mixtures thereof, with acrylic acid, methacrylic acid, and mixtures thereof being most preferred.
  • the short chain alcohol acrylate ester monomer or derivative thereof is preferably selected from the group consisting of C 1.4 alcohol acrylate esters, C1.4 alcohol methacrylate esters, C alcohol ethacrylate esters, and mixtures thereof, with the Ci .4 alcohol acrylate esters, C1.4 alcohol methacrylate esters, and mixtures thereof, being most preferred.
  • the long chain alcohol acrylate ester monomer is selected from C alkyl acrylate esters, with C ⁇ o-30 alkyl acrylate esters being 8-40 preferred.
  • the crosslinking agent in both of these types of polymers is a polyalkenyl polyether of a polyhydric alcohol containing more than one alkenyl ether group per molecule, wherein the parent polyhydric alcohol contains at least 3 carbon atoms and at least 3 hydroxyl groups.
  • Preferred crosslinkers are those selected from the group consisting of allyl ethers of sucrose and allyl ethers of pentaerythritol, and mixtures thereof.
  • Examples of commercially available homopolymers of the first type useful herein include the carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerytritol.
  • the carbomers are available as the Carbopol® 900 series from B.F. Goodrich (e.g., Carbopol® 954).
  • Examples of commercially available copolymers of the second type useful herein include copolymers of C ⁇ ⁇ -30 alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or one of their short chain (i.e. C]_4 alcohol) esters, wherein the crosslinking agent is an allyl ether of sucrose or pentaerytritol.
  • copolymers are known as acrylates/C 10-30 alkyl acrylate crosspolymers and are commercially available as Carbopol® 1342, Carbopol® 1382Pemulen TR-1, and Pemulen TR-2, from B.F. Goodrich.
  • carboxylic acid polymer thickeners useful herein are those selected from the group consisting of carbomers, acrylates/C 10-C30 alkyl acrylate crosspolymers, and mixtures thereof, (ii) Crosslinked Polyacrylate Polymers
  • the crosslinked polyacrylate polymers useful as thickeners or gelling agents include both cationic and nonionic polymers, with the cationics being generally preferred.
  • Examples of useful crosslinked nonionic polyacrylate polymers and crosslinked cationic polyacrylate polymers are those described in U.S. Patent 5,100,660, to Hawe et al., issued March 31, 1992; U.S. Patent 4,849,484, to Heard, issued July 18, 1989; U.S. Patent 4,835,206, to Farrar et al., issued May 30, 1989; U.S. Patent 4,628,078 to Glover et al. issued December 9, 1986; U.S. Patent 4,599,379 to Flesher et al. issued July 8, 1986; and EP 228,868, to Farrar et al., published July 15, 1987; all of which are inco ⁇ orated by reference herein in their entirety.
  • the crosslinked polyacrylate polymers are high molecular weight materials that can be characterized by the general formula: (A) ⁇ (B) m (C) n and comprise the monomer units (A) ⁇ , (B) m , and (C) n , wherein (A) is a dialkylaminoalkyl acrylate monomer or its quaternary ammonium or acid addition salt, (B) is a dialkylaminoalkyl methacrylate monomer or its quaternary ammonium or acid addition salt, (C) is a monomer that is polymerizable with (A) or (B), for example a monomer having a carbon-carbon double bond or other such polymerizable functional group, 1 is an integer of 0 or greater, m is an integer of 0 or greater, n is an integer of 0 or greater, but where either 1 or m, or both, must be 1 or greater.
  • the (C) monomer can be selected from any of the commonly used monomers. Nonlimiting examples of these monomers include ethylene, propylene, butylene, isobutylene, eicosene, maleic anhydride, acrylamide, methacrylamide, maleic acid, acrolein, cyclohexene, ethyl vinyl ether, and methyl vinyl ether. In the cationic polymers of the present invention, (C) is preferably acrylamide.
  • the alkyl portions of the (A) and (B) monomers are short chain length alky Is such as Cj-Cg, preferably C1-C5, more preferably C1-C3, and most preferably C1-C2.
  • the polymers are preferably quaternized with short chain alkyls, i.e., Cj-Cg, preferably C1-C5, more preferably C1 -C3, and most preferably C1 -C2.
  • the acid addition salts refer to polymers having protonated amino groups. Acid addition salts can be performed through the use of halogen (e.g. chloride), acetic, phosphoric, nitric, citric, or other acids.
  • These (A) ⁇ (B) m (C) n polymers also comprise a crosslinking agent, which is most typically a material containing two or more unsaturated functional groups.
  • the crosslinking agent is reacted with the monomer units of the polymer and is inco ⁇ orated into the polymer thereby forming links or covalent bonds between two or more individual polymer chains or between two or more sections of the same polymer chain.
  • suitable crosslinking agents include those selected from the group consisting of methylenebisacrylamides, diallyldialkyl ammonium halides, polyalkenyl polyethers of polyhydric alcohols, allyl acrylates, vinyloxyalkylacrylates, and polyfiinctional vinylidenes.
  • crosslinking agents useful herein include those selected from the group consisting of methylenebisacrylamide, ethylene glycol di-(meth)acrylate, di-(meth)acrylamide, cyanomethylacrylate, vinyloxyethylacrylate, vinyloxyethylmethacrylate, allyl penta- erythritol, trimethylolpropane diallylether, allyl sucrose, butadiene, isoprene, divinyl benzene, divinyl naphthalene, ethyl vinyl ether, methyl vinyl ether, and allyl acrylate.
  • Other crosslinkers include formaldehyde and glyoxal.
  • Preferred for use herein as a crosslinking agent is methylenebisacrylamide.
  • crosslinking agent can be employed depending upon the properties desired in the final polymer, e.g. viscosifying effect. Without being limited by theory, it is believed that inco ⁇ oration of a crosslinking agent into these cationic polymers provides a material that is a more effective viscosifying agent without negatives such as stringiness and viscosity breakdown in the presence of electrolytes.
  • the crosslinking agent when present, can comprise from about 1 ppm to about 1000 ppm, preferably from about 5 ppm to about 750 ppm, more preferably from about 25 ppm to about 500 ppm, even more preferably from about 100 ppm to about 500 ppm, and most preferably from about 250 ppm to about 500 ppm of the total weight of the polymer on a weight/weight basis.
  • the intrinsic viscosity of the crosslinked polymer measured in one molar o sodium chloride solution at 25 C, is generally above 6, preferably from about 8 to about 14.
  • the molecular weight (weight average) of the crosslinked polymers hereof is high, and is believed to typically be between about 1 million and about 30 million.
  • the specific molecular weight is not critical and lower or higher weight average molecular weights can be used as long as the polymer retains its intended viscosifying effects.
  • a 1.0% solution of the polymer (on an actives basis) in deionized water will have a viscosity at 25°C of at least about 20,000 cP, preferably at least about 30,000 cP, when measured at 20 RPM by a Brookfield RVT
  • These cationic polymers can be made by polymerization of an aqueous solution containing from about 20% to about 60%, generally from about 25% to about 40%, by weight monomer, in the presence of an initiator (usually redox or thermal) until the polymerization terminates.
  • the crosslinking agent can also be added to the solution of the monomers to be polymerized, to inco ⁇ orate it into the polymer. In the polymerization reactions, the temperature generally starts between about 0° and 95°C.
  • the polymerization can be conducted by forming a reverse phase dispersion of an aqueous phase of the monomers (and also any additional crosslinking agents) into a nonaqueous liquid, e.g. mineral oil, lanolin, isododecane, oleyl alcohol, and other volatile and nonvolatile esters, ethers, and alcohols, and the like.
  • the molar proportion of (C) monomer based on the total molar amount of (A), (B), and (C), can be from 0% to about 99%.
  • the molar proportions of (A) and (B) can each be from 0% to 100%.
  • acrylamide is used as the (C) monomer, it will preferably be used at a level of from about 20% to about 99%, more preferably from about 50% to about 90%.
  • the ratio of monomer (A) to monomer (B) in the final polymer, on a molar basis, is preferably from about 99:5 to about 15:85, more preferably from about 80:20 to about 20:80.
  • the ratio is from about 5:95 to about 50:50, preferably from about 5:95 to about 25:75.
  • the ratio (A):(B) is from about 50:50 to about 85:15.
  • the ratio (A):(B) is about 60:40 to about 85:15, most preferably about 75:25 to about 85:15.
  • monomer (A) is not present and the ratio of monomer (B):monomer (C) is from about 30:70 to about 70:30, preferably from about 40:60 to about 60:40 and most preferably from about 45:55 to about 55:45.
  • Cationic polymers that are useful herein that are especially preferred are those conforming to the general structure (A) ⁇ (B) m (C) n wherein 1 is zero, (B) is methyl quaternized dimethylaminoethyl methacrylate, the ratio of (B):(C) is from about 45:55 to about 55:45, and the crosslinking agent is methylenebisacrylamide.
  • An example of such a cationic polymer is one that is commercially available as a mineral oil dispersion (which can also include various dispersing aids such as PPG-1 trideceth-6) under the trademark Salcare® SC92 from Allied Colloids Ltd. (Norfolk, Virginia). This polymer has the proposed CTFA designation, "Polyquaternium 32 (and) Mineral Oil”.
  • cationic polymers useful herein are those not containing acrylamide or other (C) monomers, that is, n is zero.
  • the (A) and (B) monomer components are as described above.
  • An especially preferred group of these non- acrylamide containing polymers is one in which 1 is also zero.
  • the polymer is essentially a homopolymer of a dialkylaminoalkyl methacrlyate monomer or its quaternary ammonium or acid addition salt.
  • diaklylaminoalkyl methacrylate polymers preferably contain a crosslinking agent as described above.
  • a cationic polymer which is essentially a homopolymer, useful herein is one conforming to the general structure (A) ⁇ (B) m (C) n wherein 1 is zero, (B) is methyl quaternized dimethylaminoethyl methacrylate, n is zero, and the crosslinking agent is methylenebisacrylamide.
  • An example of such a homopolymer is commercially available as a mixture containing approximately 50% of the polymer, approximately 44% mineral oil, and approximately 6% PPG-1 trideceth-6 as a dispersing aid, from Allied Colloids Ltd, (Norfolk, VA) under the trademark Salcare® SC95. This polymer has recently been given the CTFA designation "Polyquaternium 37 (and) Mineral Oil (and) PPG-1 Trideceth-6".
  • Polyacrylamide Polymers Also useful herein are polyacrylamide polymers, especially non-ionic polyacrylamide polymers including substituted branched or unbranched polymers. These polymers can be formed from a variety of monomers including acrylamide and methacrylamide which are unsubstituted or substituted with one or two alkyl groups (preferably C ⁇ to C5).
  • acrylate amide and methacrylate amide monomers in which the amide nitrogen is unsubstituted, or substituted with one or two C ⁇ to C5 alkyl groups (preferably methyl, ethyl, or propyl), for example, acrylamide, methacrylamide, N-methacrylamide, N- methylmethacrylamide, N,N-dimethylmethacrylamide, N-isopropylacrylamide, N- isopropylmethacrylamide, and N,N-dimethylacrylamide.
  • These polymers have a molecular weight greater than about 1,000,000 preferably greater than about 1,5000,000 and range up to about 30,000,000.
  • polyacrylamide polymers Most preferred among these polyacrylamide polymers is the non-ionic polymer given the CTFA designation polyacrylamide and isoparaffin and laureth-7, available under the Tradename Sepigel 305 from Seppic Co ⁇ oration (F airfield, NJ).
  • Other polyacrylamide polymers useful herein include multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids. Commercially available examples of these multi-block copolymers include Hypan SR150H, SS500V, SS500W, SSSA100H, from Lipo Chemicals, Inc., (Patterson, NJ).
  • polysaccharides are useful herein.
  • polysaccharides are meant gelling agents containing a backbone of repeating sugar (i.e. carbohydrate) units.
  • Nonlimiting examples of polysaccharide gelling agents include those selected from the group consisting of cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof.
  • alkyl substituted celluloses are also useful herein.
  • the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a C10-C30 straight chain or branched chain alkyl group through an ether linkage.
  • these polymers are ethers of C10-C30 straight or branched chain alcohols with hydroxyalkylcelluloses.
  • alkyl groups useful herein include those selected from the group consisting of stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, cocoyl (i.e.
  • alkyl groups derived from the alcohols of coconut oil palmityl, oleyl, linoleyl, linolenyl, ricinoleyl, behenyl, and mixtures thereof.
  • Preferred among the alkyl hydroxyalkyl cellulose ethers is the material given the CTFA designation cetyl hydroxyethylcellulose, which is the ether of cetyl alcohol and hydroxyethylcellulose. This material is sold under the tradename Natrosol® CS Plus from Aqualon Co ⁇ oration.
  • polysaccharides include scleroglucans comprising a linear chain of (l->3) linked glucose units with a (l->6) linked glucose every three units, a commercially available example of which is ClearogelTM CS11 from Michel Mercier Products Inc. (Mountainside, NJ).
  • Gums Other additional thickening and gelling agents useful herein include materials which are primarily derived from natural sources.
  • Nonlimiting examples of these gelling agent gums include materials selected from the group consisting of acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboyxmethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.
  • crosslinked Vinyl Ether/Maleic Anhydride Copolymers Other additional thickening and gelling agents useful herein include crosslinked copolymers of alkyl vinyl ethers and maleic anhydride.
  • the vinyl ethers are represented by the formula R-O-CH—CH2 wherein R is a C1-C6 alkyl group, preferably R is methyl.
  • Preferred crosslinking agents are C4-C20 dienes, preferably C6 to C16 dienes, and most preferably C8 to C12 dienes.
  • a particularly preferred copolymer is one formed from methyl vinyl ether and maleic anhydride wherein the copolymer has been crosslinked with decadiene, and wherein the polymer when diluted as a 0.5% aqueous solution at pH 7 at 25°C has a viscosity of 50,000-70,000 cps when measured using a Brookfield RTV viscometer, spindle #7 at 10 rpm.
  • This copolymer has the CTFA designation PVM/MA decadiene crosspolymer and is commercially available as StabilezeTM 06 from International Specialty Products (Wayne NJ).
  • Crosslinked polyfN-vinylpyrrolidones Crosslinked polyvinyl(N-pyrrolidones) useful herein as additional thickening and gelling agents and include those described in U.S. Patent No. 5,139,770, to Shih et al, issued August 18, 1992, and U.S. Patent No. 5,073,614, to Shih et al, issued December 17, 1991, both patents of which are inco ⁇ orated by reference herein in their entirety.
  • These gelling agents typically contain from about 0.25% to about 1% by weight of a crosslinking agent selected from the group consisting of divinyl ethers and diallyl ethers of terminal diols containing from about 2 to about 12 carbon atoms, divinyl ethers and diallyl ethers of polyethylene glycols containing from about 2 to about 600 units, dienes having from about 6 to about 20 carbon atoms, divinyl benzene, vinyl and allyl ethers of pentaerythritol, and the like.
  • a crosslinking agent selected from the group consisting of divinyl ethers and diallyl ethers of terminal diols containing from about 2 to about 12 carbon atoms, divinyl ethers and diallyl ethers of polyethylene glycols containing from about 2 to about 600 units, dienes having from about 6 to about 20 carbon atoms, divinyl benzene, vinyl and allyl ethers of pentaerythritol,
  • these gelling agents typically have a viscosity from about 25,000 cps to about 40,000 cps when measured as a 5% aqueous solution at 25 °C using a Brookfield RVT viscometer with Spindle #6 at 10 ⁇ m.
  • Commercially available examples of these polymers include ACP-1120, ACP-1179, and ACP- 1180, available from International Specialty Products (Wayne, NJ).
  • Thickening agents which are suitable for use herein also include those disclosed in U.S. Patent No., 4,387,107, to Klein et al., issued June 7, 1983 and "Encyclopedia of Polymer and Thickeners for Cosmetics," R.Y. Lochhead and W. R. Fron, eds., Cosmetics & Toiletries, vol. 108, pp. 95-135 (May 1993), which are all inco ⁇ orated herein by reference in their entirety.
  • compositions of the present invention include a thickening agent selected from the group consisting of carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof, more preferably selected from the group consisting of crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof.
  • a thickening agent selected from the group consisting of carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof, more preferably selected from the group consisting of crosslinked polyacrylate polymers, polyacrylamide polymers, and mixtures thereof.
  • compositions of the present invention may comprise a wide variety of optional components, provided that such optional components are physically and chemically compatible with the essential components described herein, and do not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention.
  • Optional components may be dispersed, dissolved or the like in the carrier of the present compositions.
  • compositions may include, in addition to the essential components of the invention, absorbents (including oil absorbents such as clays an polymeric absorbents), abrasives, anticaking agents, antifoaming agents, antimicrobial agents (e.g., a compound capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes and useful, for example, in controlling acne and/or preserving the topical composition), binders, biological additives, buffering agents, bulking agents, chemical additives, cosmetic biocides, denaturants, cosmetic astringents, drug astringents, external analgesics, film formers, humectants, opacifying agents, fragrances, perfumes, pigments, colorings, essential oils, skin sensates, emollients, skin soothing agents, skin healing agents, pH adjusters, plasticizers, preservatives, preservative enhancers, propellants, reducing agents,
  • absorbents including oil absorbents such as clay
  • the composition also includes an active useful for chronically regulating skin condition.
  • active useful for chronically regulating skin condition are those which manifest skin appearance benefits following chronic application of the composition containing such materials.
  • Materials having this effect include, but are not limited to, Vitamin B3 compounds.
  • compositions of the present invention comprise a safe and effective amount of a vitamin B3 compound.
  • the vitamin B3 compound enhances the skin appearance benefits of the present invention, especially in regulating skin condition, including regulating signs of skin aging, more especially wrinkles, lines, and pores.
  • the compositions of the present invention preferably comprise from about 0.01% to about 50%, more preferably from about 0.1% to about 10%, even more preferably from about 0.5% to about 10%, and still more preferably from about 1% to about 5%, most preferably from about 2% to about 5%, of the vitamin B3 compound .
  • vitamin B3 compound means a compound having the formula:
  • R is - CONH2 (i.e., niacinamide), - COOH (i.e., nicotinic acid) or - CH2OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
  • CONH2 i.e., niacinamide
  • COOH i.e., nicotinic acid
  • CH2OH i.e., nicotinyl alcohol
  • Exemplary derivatives of the foregoing vitamin B3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
  • Suitable esters of nicotinic acid include nicotinic acid esters of C ⁇ -C22 > preferably C ⁇ -C ⁇ g, more preferably Cj-C alcohols.
  • the alcohols are suitably straight-chain or branched chain, cyclic or acyclic, saturated or unsaturated (including aromatic), and substituted or unsubstituted.
  • the esters are preferably non-vasodilating.
  • non-vasodilating means that the ester does not commonly yield a visible flushing response after application to the skin in the subject compositions (the majority of the general population would not experience a visible flushing response, although such compounds may cause vasodilation not visible to the naked eye, i.e., the ester is non-rubifacient).
  • Non-vasodilating esters of nicotinic acid include tocopherol nicotinate and inositol hexanicotinate; tocopherol nicotinate is preferred.
  • Other derivatives of the vitamin B3 compound are derivatives of niacinamide resulting from substitution of one or more of the amide group hydrogens.
  • Nonlimiting examples of derivatives of niacinamide useful herein include nicotinyl amino acids, derived, for example, from the reaction of an activated nicotinic acid compound (e.g., nicotinic acid azide or nicotinyl chloride) with an amino acid, and nicotinyl alcohol esters of organic carboxylic acids (e.g., Cl - C18).
  • an activated nicotinic acid compound e.g., nicotinic acid azide or nicotinyl chloride
  • nicotinyl alcohol esters of organic carboxylic acids e.g., Cl - C18
  • Specific examples of such derivatives include nicotinuric acid (CgHgN2U3) and nicotinyl hydroxamic acid (C6H N2O2), which have the following chemical structures: nicotinuric acid:
  • nicotinyl alcohol esters include nicotinyl alcohol esters of the carboxylic acids salicylic acid, acetic acid, gly colic acid, palmitic acid and the like.
  • vitamin B3 compounds useful herein are 2- chloronicotinamide, 6-aminonicotinamide, 6-methylnicotinamide, n-methyl- nicotinamide, n,n-diethylnicotinamide, n-(hydroxymethyl)-nicotinamide, quinolinic acid imide, nicotinanilide, n-benzylnicotinamide, n-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methyl isonicotinic acid, thionicotinamide, nialamide, l-(3-pyridylmethyl) urea, 2-mercaptonicotinic acid, nicomol,
  • vitamin B3 compounds are well known in the art and are commercially available from a number of sources, e.g., the Sigma Chemical Company (St. Louis, MO); ICN Biomedicals, Inc. (Irvin, CA) and Aldrich Chemical Company (Milwaukee, WI).
  • vitamin B3 compounds may be used herein.
  • Preferred vitamin B3 compounds are niacinamide and tocopherol nicotinate. Niacinamide is more preferred.
  • salts, derivatives, and salt derivatives of niacinamide are preferably those having substantially the same efficacy as niacinamide in the methods of regulating skin condition described herein.
  • Salts of the vitamin B3 compound are also useful herein.
  • Nonlimiting examples of salts of the vitamin B3 compound useful herein include organic or inorganic salts, such as inorganic salts with anionic inorganic species (e.g., chloride, bromide, iodide, carbonate, preferably chloride), and organic carboxylic acid salts (including mono-, di- and tri- Cl - C18 carboxylic acid salts, e.g., acetate, salicylate, glycolate, lactate, malate, citrate, preferably monocarboxylic acid salts such as acetate).
  • anionic inorganic species e.g., chloride, bromide, iodide, carbonate, preferably chloride
  • organic carboxylic acid salts including mono-, di- and tri- Cl - C18 carboxylic acid salts, e.g., acetate, salicylate, glycolate, lactate, malate, citrate, preferably monocarboxylic acid salts such
  • Wenner "The Reaction of L- Ascorbic and D-Iosascorbic Acid with Nicotinic Acid and Its Amide", J. Organic Chemistry, VOL. 14, 22-26 (1949), which is inco ⁇ orated herein by reference. Wenner describes the synthesis of the ascorbic acid salt of niacinamide.
  • the ring nitrogen of the vitamin B3 compound is substantially chemically free (e.g., unbound and/or unhindered), or after delivery to the skin becomes substantially chemically free ("chemically free” is hereinafter alternatively referred to as "uncomplexed”). More preferably, the vitamin B3 compound is essentially uncomplexed. Therefore, if the composition contains the vitamin B3 compound in a salt or otherwise complexed form, such complex is preferably substantially reversible, more preferably essentially reversible, upon delivery of the composition to the skin. For example, such complex should be substantially reversible at a pH of from about 5.0 to about 6.0. Such reversibility can be readily determined by one having ordinary skill in the art.
  • the vitamin B3 compound is substantially uncomplexed in the composition prior to delivery to the skin.
  • Exemplary approaches to minimizing or preventing the formation of unesirable complexes include omission of materials which form substantially irreversible or other complexes with the vitamin B3 compound, pH adjustment, ionic strength adjustment, the use of surfactants, and formulating wherein the vitamin B3 compound and materials which complex therewith are in different phases. Such approaches are well within the level of ordinary skill in the art.
  • the vitamin B3 compound contains a limited amount of the salt form and is more preferably substantially free of salts of a vitamin B3 compound.
  • the vitamin B3 compound contains less than about 50% of such salt, and is more preferably essentially free of the salt form.
  • the vitamin B3 compound in the compositions hereof having a pH of from about 4 to about 7 typically contain less than about 50% of the salt form.
  • the vitamin B3 compound may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • the vitamin B3 compound is preferably substantially pure, more preferably essentially pure.
  • a safe and effective amount of an anti-inflammatory agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 0.5% to about 5%, of the composition.
  • the anti- inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone or color.
  • the exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti-inflammatory agent utilized since such agents vary widely in potency.
  • Steroidal anti-inflammatory agents including but not limited to, corticosteroids such as hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, difiorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, cor
  • a second class of anti-inflammatory agents which is useful in the compositions includes the nonsteroidal anti-inflammatory agents.
  • the variety of compounds encompassed by this group are well-known to those skilled in the art.
  • compositions include, but are not limited to:
  • the oxicams such as piroxicam, isoxicam, tenoxicam, sudoxicam, and CP- 14,304;
  • salicylates such as aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal;
  • acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac;
  • the fenamates such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids;
  • the propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pi ⁇ rofen, ca ⁇ rofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and
  • the pyrazoles such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and trimethazone.
  • non-steroidal anti-inflammatory agents may also be employed, as well as the dermatologically acceptable salts and esters of these agents.
  • etofenamate a flufenamic acid derivative
  • ibuprofen, naproxen, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, piroxicam and felbinac are preferred; ibuprofen, naproxen, etofenamate, aspirin and flufenamic acid are most preferred.
  • so-called "natural" anti-inflammatory agents are useful in methods of the subject invention.
  • Such agents may suitably be obtained as an extract by suitable physical and/or chemical isolation from natural sources (e.g., plants, fungi, byproducts of microorganisms).
  • natural sources e.g., plants, fungi, byproducts of microorganisms.
  • candelilla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus Rubia. particularly Rubia CordifoliaV and Guggal (extracted from plants in the genus Commiphora. particularly Commiphora MukuD. kola extract, chamomile, and sea whip extract may be used.
  • Additional anti-inflammatory agents useful herein include compounds of the Licorice (the plant genus/species Glycyrrhiza glabra) family, including glycyrrhetic acid, glycyrrhizic acid, and derivatives thereof (e.g., salts and esters).
  • Suitable salts of the foregoing compounds include metal and ammonium salts.
  • Suitable esters include C2 - C24 saturated or unsaturated esters of the acids, preferably CJ Q - C24, more preferably C ⁇ - C24.
  • oil soluble licorice extract the glycyrrhizic and glycyrrhetic acids themselves, monoammonium glycyrrhizinate, monopotassium glycyrrhizinate, dipotassium glycyrrhizinate, 1- beta-glycyrrhetic acid, stearyl glycyrrhetinate, and 3-stearyloxy-glycyrrhetinic acid, and disodium 3-succinyloxy-beta-glycyrrhetinate. Stearyl glycyrrhetinate is preferred.
  • compositions of the subject invention preferably contain a sunscreen or sunblock.
  • Suitable sunscreens or sunblocks may be organic or inorganic.
  • sunscreening agents include, for example: p- aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters; p- dimethylaminobenzoic acid); anthranilates (i.e., o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, te ⁇ inyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-pro-pyleneglycol esters); cinnamic acid derivatives (menthyl and benzyl esters, a-phenyl cinnamonitrile; butyl cinnamoyl pyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methyl
  • 2-ethylhexyl-p-methoxycinnamate commercially available as PARSOL MCX
  • 4,4'-t-butyl methoxydibenzoyl-methane commercially available as PARSOL 1789
  • 2-hydroxy-4-methoxybenzophenone octyldimethyl-p- aminobenzoic acid, digalloyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4-(bis(hydroxy-propyl))aminobenzoate, 2-ethylhexyl-2-cyano-3 ,3 - diphenylacrylate, 2-ethylhexyl-salicylate, glyceryl-p-aminobenzoate, 3,3,5-tri- methylcyclohexylsalicylate, methylanthranilate, p-dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl
  • More preferred organic sunscreens useful in the compositions useful in the subject invention are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoyl- methane, 2-hydroxy-4-methoxybenzo-phenone, 2-phenylbenzimidazole-5-sulfonic acid, octyldimethyl-p-aminobenzoic acid, octocrylene and mixtures thereof.
  • sunscreens such as those disclosed in U.S. Patent No. 4,937,370 issued to Sabatelli on June 26, 1990, and U.S. Patent No. 4,999,186 issued to Sabatelli & Spirnak on March 12, 1991, both of which are inco ⁇ orated herein by reference.
  • the sunscreening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultra-violet radiation abso ⁇ tion spectra. One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range.
  • Preferred members of this class of sunscreening agents are 4-N,N-(2- ethylhexyl)methyl-arninobenzoic acid ester of 2,4-dihydroxybenzophenone; N,N-di- (2-ethylhexyl)-4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N- (2-ethylhexyl)methyl-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4- N,N-(2-ethylhexyl)methyl-aminobenzoic acid ester of 2-hydroxy-4-(2- hydroxyethoxy)benzophenone; 4-N,N-(2-ethylhexyl)-methylaminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of
  • sunscreens or sunblocks include butylmethoxydibenzoylmethane, 2-ethylhexyl-p-methoxycinnamate, phenyl benzimidazole sulfonic acid, and octocrylene.
  • a safe and effective amount of the sunscreen or sunblock is used, typically from about 1% to about 20%, more typically from about 2% to about 10%. Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF).
  • SPF Sun Protection Factor
  • compositions useful in the subject invention may also be added to any of the compositions useful in the subject invention to improve the skin substantivity of those compositions, particularly to enhance their resistance to being washed off by water, or rubbed off.
  • a preferred agent which will provide this benefit is a copolymer of ethylene and acrylic acid. Compositions comprising this copolymer are disclosed in U.S. Patent 4,663,157, Brock, issued May 5, 1987, which is inco ⁇ orated herein by reference.
  • compositions of the subject invention include an anti- oxidant/radical scavenger.
  • the anti-oxidant/radical scavenger is especially useful for providing protection against UV radiation which can cause increased scaling or texture changes in the stratum corneum and against other environmental agents which can cause skin damage.
  • a safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition.
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6- hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox ⁇ ), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, lycine pidolate, arg
  • Preferred anti-oxidants/radical scavengers are selected from tocopherol sorbate and other esters of tocopherol, more preferably tocopherol sorbate.
  • tocopherol sorbate in topical compositions and applicable to the present invention is described in U.S. Patent No. 4,847,071, issued on July 11, 1989 to Donald L. Bissett, Rodney D. Bush and Ranjit Chatterjee, inco ⁇ orated herein by reference.
  • chelating agent means an active agent capable of removing a metal ion from a system by forming a complex so that the metal ion cannot readily participate in or catalyze chemical reactions.
  • the inclusion of a chelating agent is especially useful for providing protection against UV radiation which can contribute to excessive scaling or skin texture changes and against other environmental agents which can cause skin damage.
  • a safe and effective amount of a chelating agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition.
  • Exemplary chelators that are useful herein are disclosed in U.S. Patent No. 5,487,884, issued 1/30/96 to Bissett et al.; International Publication No. 91/16035, Bush et al, published 10/31/95; and International Publication No. 91/16034, Bush et al., published 10/31/95; all inco ⁇ orated herein by reference.
  • Preferred chelators useful in compositions of the subject invention are furildioxime and derivatives thereof.
  • Compositions of the present invention may comprise an organic hydroxy acid.
  • Suitable hydroxy acids include C ⁇ - Ci g hydroxy acids, preferably Cg or below.
  • the hydroxy acids can be substituted or unsubstituted, straight chain, branched chain or cyclic (preferably straight chain), and saturated or unsaturated (mono- or poly- unsaturated) (preferably saturated).
  • suitable hydroxy acids include salicylic acid, glycolic acid, lactic acid, 5 octanoyl salicylic acid, hydroxyoctanoic acid, hydroxycaprylic acid, and lanolin fatty acids.
  • Preferred concentrations of the organic hydroxy acid range from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2%.
  • Salicylic acid is preferred.
  • the organic hydroxy acids enhance the skin appearance benefits of the present invention. For example, the organic hydroxy acids tend to improve the texture of the skin.
  • a safe and effective amount of a desquamation agent may be added to the compositions of the subject invention, more preferably from about 0.1% to about 10%, even more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 4% of the composition.
  • Desquamation agents enhance the skin appearance benefits of the present invention. For example, the desquamation agents tend to improve the texture of the skin (e.g., smoothness).
  • a variety of desquamation agents are known in the art and are suitable for use herein, including but not limited to the organic hydroxy agents described above.
  • One desquamation system that is suitable for use herein comprises sulfhydryl compounds and zwitterionic surfactants and is described in copending application Serial No.
  • compositions of the present invention may comprise a skin lightening agent.
  • the compositions preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2%, of a skin lightening agent.
  • Suitable skin lightening agents include those known in the art, including kojic acid, arbutin, ascorbic acid and derivatives thereof, e.g., magnesium ascorbyl phosphate.
  • Skin lightening agents suitable for use herein also include those described in copending patent application Serial No. 08/479,935, filed on June 7, 1995 in the name of Hillebrand, corresponding to PCT Application No. U.S. 95/07432, filed 6/12/95; and copending patent application Serial No.
  • compositions of the invention comprise an optional skin conditioning component.
  • the skin conditioning component is preferably selected from the group consisting of emollients, humectants, moisturizers and mixtures thereof.
  • the skin conditioning component is preferably present at a level of at least about 0.1%, more preferably from about 1% to about 99%, even more preferably from about 1% to about 50%, still more preferably from about 2% to about 30% and most preferably from about 5% to about 25% (e.g., about 5% to about 10% or 15%).
  • emollients may be employed. These emollients may be selected from one or more of the following classes: Triglyceride esters which include, but are not limited to, vegetable and animal fats and oils such as castor oil, cocoa butter, safflower oil, cottonseed oil, corn oil, olive oil, cod liver oil, almond oil, avocado oil, palm oil, sesame oil, squalene, kikui oil and soybean oil; Acetoglyceride esters, such as acetylated monoglycerides; Ethoxylated glycerides, such as ethoxylated glyceryl monostearate; Alkyl esters of fatty acids having 10 to 20 carbon atoms which include, but are not limited to, methyl, isopropyl, and butyl esters of fatty acids such as hexyl laurate, isohexyl laurate, isohexyl palmitate, isopropyl palmitate, methyl palmitate
  • conditioning compounds are humectants of the polyhydric alcohol-type.
  • Typical polyhydric alcohols include polyalkylene glycols and more preferably alkylene polyols and their derivatives, including propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, erythritol, threitol, pentaerythritol, xylitol, glucitol, mannitol, hexylene glycol, butylene glycol (e.g., 1,3-butylene glycol), hexane triol (e.g., 1 ,2,6-hexanetriol), glycerol, ethoxylated glycerol, propoxylated glycerol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin and mixtures
  • guanidine also useful herein are guanidine; glycolic acid and glycolate salts (e.g. ammonium and quaternary alkyl ammonium); lactic acid and lactate salts (e.g. ammonium and quaternary alkyl ammonium); aloe vera in any of its variety of forms (e.g., aloe vera gel); sugar and starch derivatives (e.g., alkoxylated glucose); hyaluronic acid and derivatives thereof (e.g., salt derivatives such as sodium hyaluraonate); lactamide monoethanolamine; acetamide monoethanolamine; urea; panthenol; sugars; starches; silicone fluids; silicone gums; and mixtures thereof.
  • glycolic acid and glycolate salts e.g. ammonium and quaternary alkyl ammonium
  • lactic acid and lactate salts e.g. ammonium and quaternary alkyl ammonium
  • compositions of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
  • compositions of the present invention are useful for regulating mammalian skin condition (especially human skin, more especially human facial skin), including visible and/or tactile discontinuities in skin, signs of skin aging, and visible and/or tactile discontinuities in skin associated with skin aging (including fine lines, wrinkles, large pores, surface roughness and other texture discontinuities associated with aged skin).
  • mammalian skin condition especially human skin, more especially human facial skin
  • visible and/or tactile discontinuities in skin including fine lines, wrinkles, large pores, surface roughness and other texture discontinuities associated with aged skin.
  • Such regulation includes prophylactic and therapeutic regulation.
  • Regulating skin condition involves topically applying to the skin a safe and effective amount of a composition of the present invention.
  • the amount of the composition which is applied, the frequency of application and the period of use will vary widely depending upon the level of retinoid and/or other components of a given composition and the level of regulation desired, e.g., in light of the level of skin aging present in the subject and the rate of further skin aging.
  • the composition is chronically applied to the skin.
  • chromenic topical application is meant continued topical application of the composition over an extended period during the subject's lifetime, preferably for a period of at least about one week, more preferably for a period of at least about one month, even more preferably for at least about three months, even more preferably for at least about six months, and more preferably still for at least about one year. While benefits are obtainable after various maximum periods of use (e.g., five, ten or twenty years), it is preferred that chronic application continue throughout the subject's lifetime. Typically applications would be on the order of about once per day over such extended periods, however application rates can vary from about once per week up to about three times per day or more.
  • compositions of the present invention can be employed to provide a skin appearance and/or feel benefit.
  • Quantities of the present compositions which are typically applied per application are, in mg composition/cm ⁇ skin, from about 0.1 mg/cm ⁇ to about 10 mg/cm ⁇ .
  • a particularly useful application amount is about 2 mg/cm ⁇ .
  • Regulating skin condition is preferably practiced by applying a composition in the form of a skin lotion, cream, cosmetic, or the like which is intended to be left on the skin for some esthetic, prophylactic, therapeutic or other benefit (i.e., a "leave-on" composition). After applying the composition to the skin, it is preferably left on the skin for a period of at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, most preferably for at least several hours, e.g., up to about 12 hours.
  • a stable topical composition is prepared from the following ingredients using conventional formulating techniques.
  • Phase A ingredients are combined and sparged using nitrogen for approximately 15 minutes.
  • Phase B ingredients are then dispersed into Phase A until uniform using propeller type mixing and heated the mixture to about 75°C.
  • Phase C ingredients are combined and heated to about 75°C.
  • the mixture of phases A and B are then blanketed with a slow, steady stream of nitrogen.
  • the Phase C ingredients are homogenized into the mixture of phases A and B using any rotor/stator type of homogenizer for approximately 15 minutes. After the 15 minutes, the mixing is switched to low ⁇ m sweep mixing.
  • phase D ingredients are combined and added to the mixture of phases A,B, and C. Once phase D is mixed and the batch mixture is homogeneous, the entire batch mixture is cooled.
  • phase E ingredients are added and homogenized.
  • phase F ingredients are added to the batch mixture.
  • phase G ingredients are combined to the batch mixture. Mixing is continued until the batch mixture is uniform.
  • the resulting composition is useful for application to the skin for delivering the retinol and to treat and improve the appearance of the skin.
  • Example 2 A stable topical composition is prepared from the following ingredients using conventional formulating techniques.
  • Phase A ingredients are combined and sparged using nitrogen for approximately 15 minutes.
  • Phase B ingredients are then dispersed into Phase A until uniform using propeller type mixing and heated the mixture to about 75 °C.
  • Phase C ingredients are combined and heated to about 75 °C.
  • the mixture of phases A and B are then blanketed with a slow, steady stream of nitrogen.
  • the Phase C ingredients are homogenized into the mixture of phases A and B using any rotor/stator type of homogenizer for approximately 15 minutes. After the 15 minutes, the mixing is switched to low ⁇ ra sweep mixing.
  • the batch mixture is homogeneous, the entire batch mixture is cooled.
  • phase D ingredients are added and homoginized.
  • phase E ingredients are added to the batch mixture.
  • the phase F ingredients are combined to the batch mixture. Mixing is continued until the batch mixture is uniform.
  • composition is useful for application to the skin for delivering the active and to treat and improve the appearance of the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
EP98922411A 1997-05-23 1998-05-18 Zusammensetzungen fuer die hautpflege Withdrawn EP0986368A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US862772 1986-05-13
US08/862,772 USH2043H1 (en) 1997-05-23 1997-05-23 Skin care compositions
PCT/US1998/010168 WO1998052536A1 (en) 1997-05-23 1998-05-18 Skin care compositions

Publications (1)

Publication Number Publication Date
EP0986368A1 true EP0986368A1 (de) 2000-03-22

Family

ID=25339299

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98922411A Withdrawn EP0986368A1 (de) 1997-05-23 1998-05-18 Zusammensetzungen fuer die hautpflege

Country Status (6)

Country Link
US (1) USH2043H1 (de)
EP (1) EP0986368A1 (de)
JP (1) JP2001517244A (de)
CN (1) CN1261779A (de)
AU (1) AU7496498A (de)
WO (1) WO1998052536A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100356697B1 (ko) * 1998-03-07 2002-12-18 주식회사 태평양 여드름에효과가있는피부용조성물
US6627586B1 (en) * 1998-07-08 2003-09-30 The Procter & Gamble Company Cleansing compositions
JP4653282B2 (ja) * 2000-05-23 2011-03-16 昭和薬品化工株式会社 ミノサイクリン含有組成物
JP2002179549A (ja) * 2000-12-12 2002-06-26 Kishohin Kagaku Kaiho Kenkyusho:Kk 皮膚外用剤
AU2002366451A1 (en) * 2001-12-19 2003-09-09 Alwyn Company, Inc. Emulsified skin care composition containing salicylic acid, lanolin oil, and propylene glycol
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1556009B2 (de) 2002-10-25 2021-07-21 Foamix Pharmaceuticals Ltd. Kosmetischer und pharmazeutischer schaum
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20040234609A1 (en) * 2003-05-14 2004-11-25 Collier Katherine D. Repeat sequence protein polymer active agent congjugates, methods and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
DE10340830B4 (de) 2003-09-04 2006-04-13 Schülke & Mayr GmbH Verbesserte mikrobizide Zusammensetzung auf Basis von Formaldehyd-Depotverbindungen und Antioxidantien
US20060034779A1 (en) * 2004-08-02 2006-02-16 Agis Industries (1983) Ltd. Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same
JP4548831B2 (ja) * 2005-01-11 2010-09-22 日光ケミカルズ株式会社 水素添加レチノイドまたは水素添加レチノイド誘導体並びにその利用
JP4968722B2 (ja) * 2006-09-22 2012-07-04 株式会社 資生堂 水中油型乳化皮膚化粧料
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
FR2910808B1 (fr) * 2006-12-29 2009-04-10 Lvmh Rech Utilisation en cosmetique de la l-2-thiohistidine ou d'un de ses derives comme agent depigmentant.
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
DE102008016709A1 (de) * 2008-03-31 2009-10-01 Sebapharma Gmbh & Co. Sonnenschutzmittel
EP2405886B8 (de) * 2009-03-11 2017-11-01 ISP Investments LLC Topische körperpflege- und pharmaziezusammensetzungen sowie anwendungen davon
BRPI1009190B1 (pt) * 2009-03-11 2017-08-01 Isp Investments Inc. Solar filter composition
EP2405884A4 (de) * 2009-03-11 2012-10-24 Isp Investments Inc SCHWEIßHEMMENDE ZUSAMMENSETZUNGEN
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
CN103432019B (zh) * 2013-08-24 2015-07-29 上海艳紫化工科技有限公司 视黄醇护肤霜
FR3030231B1 (fr) 2014-12-23 2018-08-24 L'oreal Utilisation d'un ester d'acide gras pour matifier la peau et composition comprenant cet ester
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
KR102331771B1 (ko) * 2017-09-28 2021-12-01 가부시키가이샤 만다무 반고체상 세정제
CN115697290A (zh) 2020-05-29 2023-02-03 联合利华知识产权控股有限公司 针对视黄酸前体具有增强的颜色稳定性的化妆品组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5375339A (en) 1976-12-15 1978-07-04 Matsushita Electric Works Ltd Hair conditioning lotion
CH632668A5 (de) 1977-12-09 1982-10-29 Hoffmann La Roche Kosmetisches mittel.
US4603146A (en) 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4678663A (en) 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
US4888342A (en) 1984-05-16 1989-12-19 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4826828A (en) 1985-04-22 1989-05-02 Avon Products, Inc. Composition and method for reducing wrinkles
EP0224504B1 (de) 1985-04-22 1992-03-18 Avon Products, Inc. Zusammensetzung und verfahren zum herabsetzen von falten
JP2622955B2 (ja) 1986-07-29 1997-06-25 エイボン プロダクツ インコ−ポレイテツド 無水化粧品
US4889847A (en) 1986-11-03 1989-12-26 Ortho Pharmaceutical Corporation Prevention of glucocorticoid-induced skin atrophy
US5385938B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4960764A (en) 1987-03-06 1990-10-02 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
US4720353A (en) 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US4844891A (en) * 1988-02-03 1989-07-04 Lonza, Inc. Admixtures of iodopropargyl compounds and a formaldehyde donor
NZ227994A (en) 1988-02-16 1990-09-26 Richardson Vicks Inc Skin conditioning composition comprising glycerin and a silicone fluid phase
ES2059721T3 (es) 1988-02-25 1994-11-16 Beecham Group Plc Composicion para el tratamiento de la piel.
DE3817623A1 (de) 1988-05-25 1989-11-30 Bayer Ag Kosmetisches praeparat auf basis von retinolpalmitat
GB8821129D0 (en) 1988-09-09 1988-10-12 Unilever Plc Cosmetic composition
MY106263A (en) 1989-01-19 1995-04-29 Ortho Pharma Corp Method for the treatment or prevention of intrinsically aged skin with retinoids
FI903483A0 (fi) * 1989-07-13 1990-07-10 Bristol Myers Squibb Co Tretinoin innehaollande stabila emulsionskraemformulationer.
GB8927703D0 (en) 1989-12-07 1990-02-07 Unilever Plc Cosmetic composition
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
GB9109733D0 (en) 1991-05-07 1991-06-26 Unilever Plc Cosmetic composition
US5118507A (en) 1991-06-25 1992-06-02 Elizabeth Arden Co., Division Of Conopco, Inc. Silicone based cosmetic composition
JP3435510B2 (ja) 1991-06-27 2003-08-11 ジヨンソン・アンド・ジヨンソン・コンシユーマー・プロダクツ・インコーポレーテツド スキンケア組成物
US5296500A (en) 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
TW403660B (en) 1992-07-13 2000-09-01 Shiseido Corp External skin treatment composition
GB9223235D0 (en) 1992-11-05 1992-12-16 Unilever Plc Cosmetic composition
US5411991A (en) 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
FR2714595B1 (fr) 1993-12-30 1996-02-02 Oreal Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement.
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
US5552425A (en) 1994-04-28 1996-09-03 Isp Chemicals Inc. Synergistic water soluble preservative compositions of biocidal mixtures
US5428050A (en) * 1994-04-28 1995-06-27 Isp Chemicals Inc. Synergistic water soluble preservative compositions of biocidal mixtures
CZ365996A3 (en) 1994-06-15 1997-10-15 Procter & Gamble Use of mercapto derivatives for preparing pharmaceutical preparation for making lighter of skin
DE69524755D1 (de) 1994-06-23 2002-01-31 Procter & Gamble Topisch anzuwendende zubereitungen enthaltend n-acetyl-l-cystein
US6080393A (en) 1994-07-09 2000-06-27 Johnson & Johnson Consumer Products, Inc. Skin care composition comprising a retinoid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9852536A1 *

Also Published As

Publication number Publication date
WO1998052536A1 (en) 1998-11-26
CN1261779A (zh) 2000-08-02
JP2001517244A (ja) 2001-10-02
USH2043H1 (en) 2002-08-06
AU7496498A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
US5968528A (en) Skin care compositions
USH2043H1 (en) Skin care compositions
USH2013H1 (en) Skin care compositions
EP0983053B1 (de) Hautpflegemittel und verfahren zur verbesserung des aussehens der haut
EP0983049B2 (de) Hautpflegemittel und verfahren zur verbesserung des hauterscheinungsbildes
US6001377A (en) Skin care compositions and method of improving skin appearance
EP0896522B1 (de) Verfahren und regelung des hautaussehens mit vitamin - b3 - verbindungen
US5939082A (en) Methods of regulating skin appearance with vitamin B3 compound
US5972359A (en) Skin care compositions and method of improving skin appearance
US6238678B1 (en) Methods of regulating skin appearance with vitamin B3 compound
EP1032352B2 (de) Hautpflegezusammensetzungen und methode für die verbesserung des hautaussehens
MXPA99010838A (en) Skin care compositions and method of improving skin appearance
EP0983050B1 (de) Hautpflegemittel und verfahren zur verbesserung des aussehens der haut
MXPA99010843A (en) Skin care compositions
MXPA99010839A (en) Skin care compositions comprising vitamin b3 and a preservative
MXPA99010835A (en) Skin care compositions and method of improving skin appearance
WO1999052502A1 (en) Skin care compounds and compositions comprising such compounds
MXPA99010837A (en) Skin care compositions and method of improving skin appearance
WO1999052501A1 (en) Skin care compositions comprising a hydrophobic metal ion chelator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020903

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030114